{
    "nctId": "NCT04638725",
    "briefTitle": "Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer",
    "officialTitle": "Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 9000,
    "primaryOutcomeMeasure": "Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria:\n\nInclusion Criteria:\n\n* Age \u2265 18 years\n* Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable.\n* Current or prior treatment with one therapy targeting HER2 in adjuvant or neoadjuvant phase for the current breast cancer\n* Given written informed consent\n\nExclusion Criteria:\n\n* Patients not able to comply to the protocol assessments for geographic, social or psychological reasons\n* Patients placed under judicial protection, guardianship, or supervision\n* History of cancer in the 5 years preceding anti-HER2 therapy initiation\n* Concomitant cancer (except for an other non metastatic cancer treated only with surgery)\n\nNote : Patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant chemotherapy started after 01/01/2019. Patients treated with trastuzumab, pertuzumab, neratinib or T-DM1 in a clinical trial are eligible in the SIGHER study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}